dc.contributor.author | Adair, Gina | eng |
dc.contributor.author | Grant, Joel | eng |
dc.contributor.author | Pandhi, Nancy | eng |
dc.contributor.author | Saunders, Robert | eng |
dc.contributor.author | Sadowsky, Iris | eng |
dc.contributor.author | West, Brian | eng |
dc.contributor.author | Kerns, J. William | eng |
dc.contributor.author | Knight, Karen | eng |
dc.date.issued | 2004 | eng |
dc.description.abstract | Thrombolytic therapy should be limited to patients with acute ischemic stroke who meet strict inclusion and exclusion criteria and who can adhere to strict treatment protocol. Patients treated under these conditions have improved combined mortality and disability outcomes at 1 year when treated with recombinant tissue plasminogen activator (rtPA) (number needed to treat [NNT]=18; 95% confidence interval [CI], 11-56) (strength of recommendation [SOR]: B, meta-analysis of randomized controlled trials with significant heterogeneity). | eng |
dc.identifier.uri | http://hdl.handle.net/10355/3216 | eng |
dc.language | English | eng |
dc.publisher | Family Physicians Inquiries Network | eng |
dc.relation.ispartofcollection | Clinical Inquiries, 2004 (MU) | eng |
dc.relation.ispartofcommunity | University of Missouri--Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Network | eng |
dc.relation.ispartofseries | Journal of family practice, 53, no. 08 (August 2004): 656+. | eng |
dc.rights | OpenAccess. | eng |
dc.rights.license | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License. | eng |
dc.subject | recombinant tissue plasminogen activator (rtPA) | eng |
dc.subject | treatment protocol | eng |
dc.subject | morbidity | eng |
dc.subject.lcsh | Fibrinolytic agents | eng |
dc.subject.lcsh | Cerebrovascular disease | eng |
dc.subject.lcsh | Thrombolytic therapy | eng |
dc.title | When should patients with stroke receive thrombolytics? | eng |
dc.type | Article | eng |